Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.Journal of the American College of Cardiology|August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 TrialConnie N Hess, Stefan James, Renato D Lopes, et al.Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.Journal of the American Heart Association|December 3, 2015
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialMeena P Rao, Sigrun Halvorsen, Daniel Wojdyla, et al.JAMA Cardiology|March 30, 2017
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical TrialPatricia A Cowper, Shubin Sheng, Renato D Lopes, et al.Journal of the American College of Cardiology|March 25, 2017
Potent P2Y<sub>12</sub> Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized TrialsEmily S Lau, Eugene Braunwald, Sabina A Murphy, et al.Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.Pageof 10